Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat The 3 Penny Stocks You Swore You'd Never Buy (But You'll Check Anyway)Authored by Chris Markoch. Article Published: 1/18/2026. 
Article Highlights - Vaxart is a clinical-stage biotech developing oral vaccines that could transform global immunization if its platform proves effective.
- Microvision develops cost-effective lidar technology for autonomous vehicles, with upside tied to industry adoption and potential partnerships.
- Datavault AI focuses on monetizing digital data through AI and blockchain tools, offering speculative exposure to the emerging data-as-an-asset theme.
Penny stocks attract speculative investors seeking high-risk, high-reward opportunities. That often means betting on companies with disruptive technologies, exposure to an emerging trend, or a compelling turnaround story. Many of these companies will never survive or scale, but if one hits, investors can see outsized returns. For investors who believe strength lies in numbers, MarketBeat offers a tool that lists the 100 Most Popular Penny Stocks, ranked by the number of MarketBeat subscribers following each company. While popularity is no guarantee of success, it can give investors more conviction in a stock's potential. On September 14th, 2023, something big happened that didn't make the news. The price gap between London gold and Shanghai gold blew out to $120 an ounce. For years, that gap was a few dollars, maybe $5 or $10. A 20x jump in seconds isn't a glitch, it's the system breaking. Traders tried to buy gold in London to sell in Shanghai, but hit a wall. The London vaults were empty. Since that day, gold has hit 53 all-time highs. One stock is positioned to capture the bulk of this wealth transfer. See the full story on this opportunity now. Some investors use a $5 threshold to define penny stocks, but the stocks in this screener follow the traditional definition: stocks trading below $1. These names are highly volatile. Be sure to do your own research and understand your risk tolerance before initiating a position. Vaxart: A Potential Game-Changer for Global Immunization Efforts Vaxart Inc. (NASDAQ: VXRT) is a clinical-stage biotechnology company developing oral vaccines for infectious diseases, including influenza, norovirus, and COVID-19. Unlike traditional injected vaccines, Vaxart's tablet-based platform aims to simplify distribution and improve global accessibility. The bull case for Vaxart centers on its innovative approach. If the company can secure FDA approval and successfully scale, its oral vaccines could reduce logistical barriers to mass immunization and open the door to significant licensing or commercial partnerships. Positive trial data or a collaboration could materially shift sentiment and valuation, given the stock's low base. Clinical risk, however, remains the primary challenge. Vaxart has yet to bring a product to market, and vaccine development is costly and unpredictable. Competition from larger, better-funded players also limits visibility. For now, Vaxart is more of a long-term speculative bet on platform validation than a near-term path to profitability. The MarketBeat analyst ratings for Vaxart show only a single analyst covering the stock. That's not uncommon for small biotechs, but it should raise investors' concerns. VXRT also has only 18% institutional ownership. On the plus side, the stock has about 2% short interest, which may temper some volatility. Microvision: Developing Cost-Effective LiDAR Units for Autonomous Driving Microvision Inc. (NASDAQ: MVIS) develops LiDAR (light detection and ranging) sensors for autonomous vehicles, smart infrastructure, and industrial sensing. The company's hardware and software enable precise 3D mapping needed for self-driving and advanced driver-assistance systems (ADAS). Microvision focuses on building compact, cost-effective LiDAR units that could appeal to automakers seeking scalable sensor solutions. The bull case for Microvision rests on two themes: the continued push toward vehicle automation and the potential to secure partnerships with major automotive manufacturers. If the company can demonstrate performance or cost advantages, it could land supply agreements or licensing deals that improve revenue visibility. Microvision's technology may also find uses in robotics and smart-city applications, adding optionality to its growth story. Still, Microvision faces stiff competition from LiDAR players such as Luminar (NASDAQ: LAZR), Innoviz (NASDAQ: INVZ), and Ouster (NYSE: OUST). The path to profitability is uncertain, and recurring delays in LiDAR adoption have frustrated investors. MVIS is covered by three analysts and has a consensus price target of $2.50, implying a roughly 169% upside from its Jan. 15 close. Like many speculative names, Microvision shows relatively low institutional ownership (around 30%) and high short interest (around 21%), all of which suggest investors should expect elevated volatility. Datavault AI: Trying to Democratize Data Ownership Datavault AI Inc. (NASDAQ: DVLT) operates at the intersection of artificial intelligence, data monetization, and digital asset management. The company helps organizations turn raw data into tradable, revenue-generating assets through its patented Datavault platform. By combining AI, blockchain, and analytics, Datavault AI aims to democratize data ownership and unlock monetization opportunities that traditional systems overlook. The bullish thesis for Datavault AI rests on its niche focus and scalability potential. As data becomes an increasingly valuable commodity, businesses and individuals are seeking ways to safely monetize digital information. Datavault's technology could benefit from broader AI adoption and heightened awareness of data sovereignty. Early traction or strategic partnerships could catalyze investor confidence. That said, Datavault AI operates in a highly experimental space. Its business model is still evolving, and the path to meaningful revenue is unproven. Institutions own less than 1% of the stock, and short interest exceeds 16% as of this writing. Investors considering DVLT should treat it as a long-term, speculative position based on belief in the data-as-an-asset thesis rather than near-term earnings potential.
| 
